期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Will Transcatheter Aortic Valve Replacement(TAVR)be the Primary Therapy for Aortic Stenosis? 被引量:1
1
作者 jose f.condado Peter C.Block 《Cardiovascular Innovations and Applications》 2016年第B05期273-284,共12页
Transcatheter aortic valve replacement(TAVR)is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis(AS)or failing surgical bioprosthesis(valve-in-valve,VIV-TAVR).... Transcatheter aortic valve replacement(TAVR)is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis(AS)or failing surgical bioprosthesis(valve-in-valve,VIV-TAVR).In TAVR,the collapsed transcatheter heart valve(THV)is introduced using the delivery system inserted from the femoral artery(preferred)or other alternative accesses(transapical,transaortic,transcarotid,subclavian/transinnominate or transcaval).The delivery system is then advanced until coaxially aligned with the aortic annulus,where the THV is deployed.This procedure can be associated with complications such as access site injury(vascular complication),paravalvar leak,cerebrovascular events and conduction disturbances.However,the rapid acceptance and successes observed with TAVR have been made possible through careful patient selection,preprocedural planning(i.e.MDCT annular sizing),THV technology(i.e.new generation valves),and procedural techniques(i.e.minimalist TF-TAVR and alternative percutaneous access options),as well as a decrease in complications as TAVR experience grows.Though the results or ongoing clinical trials evaluating TAVR in intermediate surgical risk patients are pending,it is likely that TAVR will soon be approved for lower risk patients as well. 展开更多
关键词 AORTIC STENOSIS TRANSCATHETER AORTIC VALVE REPLACEMENT valve-in-valve
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部